| Literature DB >> 27042835 |
L Boudin1, A Gonçalves1,2,3, R Sabatier1,2, J Moretta4, P Sfumato5, P Asseeva4, D Livon4, F Bertucci1,2,3, J-M Extra1, C Tarpin1, G Houvenaeghel2,3,6, E Lambaudie2,3,6, A Tallet7, M Resbeut7, H Sobol3,4, E Charafe-Jauffret2,3,8, B Calmels2,9,10, C Lemarie9,10, J-M Boher5, P Viens1,2,3, F Eisinger2,3,4, C Chabannon2,3,8,9.
Abstract
Breast cancer carrying BRCA mutation may be highly sensitive to DNA-damaging agents. We hypothesized a better outcome for BRCA-mutated (BRCA(mut)) metastatic breast cancer (MBC) patients receiving high-dose chemotherapy and autologous hematopoietic stem cell transplantation (HDC AHSCT) versus unaffected BRCA (BRCA wild type; (BRCA(wt))) or patients without documented BRCA mutation (BRCA untested (BRCA(ut))). All female patients treated for MBC with AHSCT at Institut Paoli-Calmettes between 2003 and 2012 were included. BRCA(mut) and BRCA(wt) patients were identified from our institutional genetic database. Overall survival (OS) was the primary end point. A total of 235 patients were included. In all, 15 patients were BRCA(mut), 62 BRCA(wt) and 149 BRCA(ut). In multivariate analyses, the BRCA(mut) status was an independent prognostic factor for OS (hazard ratio (HR): 3.08, 95% confidence interval (CI): 1.10-8.64, P=0.0326) and PFS (HR: 2.52, 95% CI :1.29-4.91, P=0.0069). In this large series of MBC receiving HDC AHSCT, we report a highly favorable survival outcome in the subset of patients with documented germline BRCA mutations.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27042835 DOI： 10.1038/bmt.2016.82
Source DB: PubMed Journal: Bone Marrow Transplant ISSN： 0268-3369 Impact factor: 5.483